On September 15, 2026, Johnson & Johnson (NYSE: JNJ) announced encouraging results from its Phase 2b COPERNICUS study, demonstrating the benefits of less freque...
Market Samachar is a news aggregator. This article was originally published by gurufocus.com. Tap the button above to read the full story on their site.